Skip to content
AIPressRoom

FundingHealthcare & Biotech

Sensydia Closes Over $6M to Advance Cardiac Assessment System

Sensydia closed over $6M Seed financing led by Colle Capital Partners to advance its Cardiac Performance System toward FDA authorization.

By Raina Gimmel

Sensydia raises Over $6M

The big picture: Sensydia, a clinical-stage medical technology company, has closed over $6 million in an oversubscribed initial financing round. The funding will support the company’s Cardiac Performance System (CPS) through its ACOUSTIC-1 clinical study and toward U.S. Food and Drug Administration (FDA) authorization.

Why it matters:

  • Non-invasive assessment: Sensydia aims to make cardiac pressure assessments available in routine clinical settings without requiring invasive catheterization, addressing a critical need for accessible diagnostics.
  • Early diagnosis: The technology is designed to provide pulmonary pressure information, aiding clinicians in identifying congestion, supporting diagnosis, and guiding treatment decisions for patients with heart failure and pulmonary hypertension.
  • Reimbursement pathway: The introduction of Category III CPT code 1036T for non-invasive hemodynamic assessments could support the adoption and reimbursement of technologies like Sensydia’s CPS.

How it works:

  • AI-powered analysis: The Cardiac Performance System assesses heart function by collecting acoustic and electrical signals, which are then processed through artificial intelligence algorithms to provide critical pulmonary pressure information.
  • Clinical validation: Sensydia’s development program builds on catheterization-derived data, considered the clinical reference standard, and has received FDA Breakthrough Device designation to facilitate its review.
  • Point-of-care data: By enabling non-invasive measurements, CPS aims to provide objective pressure information directly in physicians’ offices, allowing for more informed therapy decisions during routine patient encounters.

The catch: While the financing positions Sensydia to advance its technology, the CPS still requires completion of its ACOUSTIC-1 clinical study and full FDA authorization before commercial launch. The new CPT code establishes a procedure for reporting but does not guarantee insurance coverage or reimbursement, which will be crucial for market adoption in a competitive medtech landscape.

Key Facts

AIPressRoom Weekly

Every round we reported this week, the people behind the companies, and the events coming up. One email, every Tuesday.

More in Healthcare & Biotech

All